YourChoice Therapeutics

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

All edits by  Dawson Sewell 

Edits on 8 January, 2020
Dawson Sewell
Dawson Sewell edited on 8 January, 2020 3:23 pm
Edits made to:
Infobox (+4/--1 properties)
Infobox
Company status
Active
Founded date
2018
Industry
Edits on 3 April, 2019
Dawson Sewell
Dawson Sewell edited on 3 April, 2019 1:14 pm
Edits made to:
Infobox (+2 properties)
Article (+876/-653 characters)
Further reading (+1 rows) (+5 cells) (+195 characters)
Related Topics (+1 topics)
Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

YourChoice Therapeutics is a biotechnology company that was one of the 2018 CITRIS Foundry Startups founded by Akash Bakshi, Nadja Mannowetz, and Polina Lishko.

...

One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Funding

Seed

On January 1, 2019 YourChoice Therapeutics completed a seed funding round with $550,000 in funding from Y Combinator.

Further reading

Title
Author
Link
Type

Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids

Pnas

Web

YourChoice Therapeutics is developing unisex, non-hormonal birth control

Kate Clark

Web

Infobox
Related Topics
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.